VarmX Appoints John Glasspool as CEO to Steer Next Phase of Growth

VarmX, a Netherlands-based biotech company pioneering treatments to address the needs of patients on oral anticoagulants, has announced the appointment of John Glasspool as its new CEO. Johannes Glasspool brings substantial expertise in the biopharmaceutical sector, previously serving as CEO of Anthos Therapeutics, where he skillfully led the company through several critical phases, including successful fundraising and advanced-stage clinical trials. With over three decades of industry experience in global biopharma, John has held influential roles at major pharmaceutical firms such as Johnson & Johnson, Novartis, and Baxter. His illustrious career also includes strategic advisory positions across several biotech firms and industry organizations. VarmX's Chairman, Dr. Jan P. M. Hørstøm, emphasized John Glasspool's relevant experience in coagulation therapies as the company gears up for a Series C fundraising round and pivotal clinical trials for their lead compound, VMX-C001. This compound targets spontaneously severe bleeding and surgical blood management for patients on oral factor Xa inhibitors. John Glasspool expressed his enthusiasm for leading VarmX during this pivotal phase aimed at advancing and commercializing the company's innovative hemostatic treatments.